You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

6 Results
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Ipilimumab - Previously Untreated Advanced Unresectable Melanoma
New Drug Funding Program
    Ipilimumab - Previously Treated Advanced Unresectable Melanoma
Aug 2024
Regimen
Cancer Type:
Sarcoma, 
Giant Cell Tumour
Intent: Curative
Aug 2024
Regimen
Cancer Type:
Breast, 
Genitourinary, 
Renal cell / Kidney, 
Lung, 
Non-Small Cell, 
Small Cell, 
Unknown Primary
Intent: Palliative
Aug 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Aug 2024
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
New Drug Funding Program
    Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
New Drug Funding Program
    Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Aug 2024
Drug
Other Name(s): Yervoy®
Aug 2024